• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter
HUMIDIFIER FILTER
Oil fume adsorption filter

FDA Accepts sNDA for the De Novo Indication for ENVARSUS XR

americanpharmaceuticalreviewApril 23, 2018

Tag: FDA , sNDA

Veloxis announced the U.S. Food & Drug Administration (FDA) has accepted for standard review the company's supplemental New Drug Application (sNDA) which seeks a new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants. This indication is commonly referred to as the de novo indication. As previously announced, the sNDA was submitted to the FDA on March 7, 2018. FDA has set a target review date under the Prescription Drug User Fee Act (PDUFA) of January 7, 2019.

Register as Visitor to CPhI China 2018!

Previous:Mundipharma CEO maintains position in the Power List

Next:FDA Takes Steps to Advance Development of Products for Treating OUD

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

FDA Accepts sNDA for the De Novo Indication for ENVARSUS XR | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Tacrolimus (FDA)

Tacrolimus (FDA)
Eptifibatide acetate USFDA china manufacture 99%min

Eptifibatide acetate USFDA china manufacture 99%min
99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0

99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0
Irinotecan Hcl trihudrate (FDA)

Irinotecan Hcl trihudrate (FDA)
Fully compliant FDA 21 CFR part 11 handheld raman spectrometer

Fully compliant FDA 21 CFR part 11 handheld raman spectrometer
Vinorelbine tartrate (FDA)

Vinorelbine tartrate (FDA)
9,9-Bis(4-aminophenyl) Fluorene (FDA)

9,9-Bis(4-aminophenyl) Fluorene (FDA)
Deoxycyline (FDA)

Deoxycyline (FDA)
Simvastatin (FDA)

Simvastatin (FDA)
Mesnaum (FDA)

Mesnaum (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service